Who Will Lead the FDA Under the Trump Administration?
Two names are being floated as likely replacements for the current FDA commissioner: Scott Gottlieb, MD, a resident scholar with the American Enterprise Institute, and Jim O’Neill, a managing director at Mithril Capital, a global investment firm.
Confirmed in
Currently, 2 names are being floated as likely replacements for Califf: the first is Scott Gottlieb, MD, a resident scholar with the American Enterprise Institute, who has previously served as deputy commissioner of medical and scientific affairs at the FDA. The other name that has surfaced is Jim O’Neill, a managing director at Mithril Capital, a global investment firm, who is far removed from the characteristics of a typical candidate for this position—O’Neill has not been trained in the medical sciences and his career history includes stints within the education field, but also
At The American Journal of Managed Care®’s Patient-Centered Oncology Care® meeting in November,
Expressing his views on the sky-rocketing drug prices,
O’Neill, according to
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Iron Dysregulation Linked to MS Progression, Review Finds
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025